PRME
Prime Medicine·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Stock Price Surged Significantly
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PRME
Prime Medicine, Inc.
A biotechnology company that focused on cure genetic disorders by deploying Prime Editing technology
60 First Street, Cambridge, MA 02141
--
Prime Medicine, Inc., was incorporated in Delaware in September 2019. The company is a biotechnology company dedicated to delivering a new class of differentiated one-time therapeutic gene therapies — Prime Editors, which address the broadest spectrum of diseases by deploying Prime Editing technology.
Company Financials
EPS
PRME has released its 2025 Q3 earnings. EPS was reported at -0.32, versus the expected -0.25, missing expectations. The chart below visualizes how PRME has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PRME has released its 2025 Q3 earnings report, with revenue of 1.23M, reflecting a YoY change of 486.12%, and net profit of -50.58M, showing a YoY change of 3.69%. The Sankey diagram below clearly presents PRME's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
